Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will release its financial results for Q1 2021 on May 10, 2021, prior to market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will release its financial results for Q1 2021 on May 10, 2021, prior to market opening. The results will be followed by a conference call at 9:00 a.m. ET to discuss financial outcomes and business highlights. Interested parties can join the call by dialing specific numbers or through a live webcast available on the company's website.
The replay will be accessible until May 16, 2021. Founded in 2007 and based in Cambridge, MA, Akebia focuses on developing therapeutics for kidney disease.
Details
News Market Reaction – AKBA
The recorded move for AKBA in the trading session of this news was +0.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2021, on Monday, May 10, 2021 before the opening of the financial markets.
Akebia will host a conference call at 9:00 a.m. Eastern Time on Monday, May 10, to discuss its first quarter financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 6250159. The call will also be webcast LIVE and can be accessed via the Investors section of the Company's website at http://ir.akebia.com.
A replay of the conference call will be available two hours after the completion of the call through May 16, 2021. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 6250159. An online archive of the conference call can be accessed via the Investors section of the Company's website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Investor Contact
Kristen K. Sheppard, Esq
ir@akebia.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-first-quarter-2021-financial-results-and-discuss-recent-business-highlights-301278435.html
SOURCE Akebia Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.